• • Company Profile
  • Executive Management
  • Board of Directors
  • Scientific Advisory Board
  • NexMed USA
  • TOTECT
• • NexACT®
  • DDAIP.HCl Properties
  • DDAIP.HCl Molecular Interactions
  • DDAIP: Mechanism of Action
  • NexACT® Diagram
  • Publications
• • Sexual Dysfunction
  • Oncology
  • Autoimmune/Anti-Inflammatory/Pain
  • Anti-Infectives & Cosmeceuticals
  • Metabolic Diseases
  • TOTECT
• • Stock Quotation
  • Interactive Chart
  • Fact Sheet
  • SEC Filings
  • SEC Filings - XBRL Content
  • Corporate Governance
  • Corporate Presentation
  • Social Media
• • Media & Events
  • Press Releases

• Patented: based on proprietary permeation enhancers that are biodegradable, biocompatible, non-toxic ingredients that mimic the composition of human skin and tissues.
  
  
• Effective: enables rapid absorption of high concentrations of drug directly to target site or systemically into blood stream.
  
  
• Safe: excellent pre-clinical and clinical safety dossiers through thousands of patient exposures
  
  
• Versatile: effective with wide range of drugs classes and different routes
  • Small molecules, peptides, proteins, SiRNA, anti-sense, and antibodies
  • Transdermal, Oral, Sub-Q, Buccal, Rectal, Nasal, Ophthalmic

NexACT^®, a clinically validated multi-route drug delivery technology, utilizes patented highly effective, novel excipients or "penetration enhancers" to dramatically improve absorption and bioavailability of drugs. Varying the concentration of the enhancer allows for local or systemic delivery of drug, as desired.

The NexACT^® technology allows:

1. Topical/transdermal delivery of drugs (even proteins),
2. Subcutaneous delivery of drugs in a depot-like fashion with improved bioavailability, and
3. Oral delivery of poorly permeable/soluble compounds including compounds belonging to BCS 2 to 4 categories.

Our most advanced enhancer- "DDAIP HCl", is currently in use in formulations containing from small molecule to proteins, antibodies and RNAi therapeutics, and has been clinically evaluated in close to 5,000 subjects and over 150 pharm/tox studies.

NexACT^® utilizes biodegradable excipients, that when incorporated into drug formulations, will help overcome the body's natural barrier properties and enable rapid penetration of high concentrations of active drug directly through the skin and major biological membranes, resulting in more effective therapies. Future applications of the NexACT^®technology will be driven primarily by in-house development strategy and through out-licensing to pharmaceutical and biotechnology companies worldwide.

The NexACT^® clinically validated Multi-route drug delivery system represents an important breakthrough in improving the delivery of compounds currently administered via alternate routes by improving bioavailability and penetration. The NexACT^® technology may allow conversion from IV delivery, thereby allowing patient self-administration and, potentially, Part D Reimbursement. The patented technology utilizes the same proven ingredients as in our transdermal formulations, DDAIP HCl. Varying concentrations of the active excipient in NexACT^® will lead to formulations that slowly release or enhance delivery of the active drug into systemic circulation.

Results from a United States Pharmacopeia Preservative Efficacy Test (USP PET) qualified NexACT^® as an anti-microbial preservative. The results show that NexACT^® was effective in killing more than 23 strains of bacteria, fungus and mold, well beyond the requirements for passing the USP PET. These results are supported by the Company's prior, long-term stability and microbiology data, generated from its clinical batches of Vitaros^®

The NexACT^® skin penetration enhancer molecules are alkyl N, N-dimethylaminoacetates (esters of fatty alcohols and amino acids) and N, N-dimethylalkanol esters of alkanoic acids (esters of fatty acids and amino alcohols). Chemically, they are similar to the structure of the two building blocks of the human anatomy, namely proteins and lipids. In principle, the proteins and the lipids are composed of amino acids or alcohols and fatty acids, respectively. Therefore, the NexACT^® enhancers are structurally similar and biologically compatible.

The NexACT^® permeation enhancer molecules are designed to be non-toxic and readily metabolized by the body. A battery of more than 100 acute, sub-acute, and chronic toxicological and pharmacological studies in numerous animal species using different routes of administration have been completed on our most advanced enhancer, NexACT. Results from these preclinical studies, and the more than 5,000 clinical subjects evaluated, strongly support the safety of NexACT^®.